欧盟上市药品（最近更新）
按更新时间最近更新
| 药品名称 | 活性成分 | 商品名 | 生产企业 | 审评状态 | 批准日期 | 更新日期 | 产品编号 | 治疗领域 | 适应症 |
|---|---|---|---|---|---|---|---|---|---|
| fezolinetant | fezolinetant | Veoza | Astellas Pharma Europe B.V. | Authorised | 2023-12-07 | 2026-08-21 | EMEA/H/C/005851 | Menopause、Hot Flashes | Veoza is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. |
| aripiprazole | aripiprazole | Aripiprazole Sandoz | Sandoz GmbH | Authorised | 2015-08-20 | 2026-08-21 | EMEA/H/C/004008 | Schizophrenia、Bipolar Disorder | Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older. |
| aflibercept | aflibercept | Eylea | Bayer AG | Authorised | 2012-11-21 | 2026-08-21 | EMEA/H/C/002392 | Wet Macular Degeneration、Macular Edema、Diabetes Complications、Retinal Vein Occlusion、Choroidal Neovascularization | Eylea 114.3 mg/ml solution for injection and Eylea 114.3 mg/ml solution for injection in pre-filled syringeEylea is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD)visual impairment due to diabetic macular oedema (DME)visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO)Eylea 40 mg/mL solution for injection in pre-filled syringeEylea is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD)visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)visual impairment due to diabetic macular oedema (DME)visual impairment due to myopic choroidal neovascularisation (myopic CNV)Eylea is indicated in preterm infants for the treatment ofretinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) diseaseEylea 40 mg/mL solution for injection in a vialEylea is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD)visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)visual impairment due to diabetic macular oedema (DME)visual impairment due to myopic choroidal neovascularisation (myopic CNV) |
| ixekizumab | ixekizumab | Taltz | Eli Lilly and Company (Ireland) Limited | Authorised | 2016-04-25 | 2026-08-21 | EMEA/H/C/003943 | Psoriasis、Arthritis, Psoriatic、Axial Spondyloarthritis、Arthritis, Juvenile | Plaque psoriasisTaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Paediatric plaque psoriasisTaltz is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.Psoriatic arthritisTaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.Axial spondyloarthritisAnkylosing spondylitis (radiographic axial spondyloarthritis)Taltz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritisTaltz is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Juvenile psoriatic arthritis (JPsA)Taltz, alone or in combination with methotrexate, is indicated for the treatment of active JPsA in patients 6 years of age and older and with a body weight of at least 25 kg, who have had an inadequate response to, or who are intolerant of, conventional therapy.Enthesitis-related arthritis (ERA)Taltz, alone or in combination with methotrexate, is indicated for the treatment of active ERA in patients 6 years of age and older and with a body weight of at least 25 kg, who have had an inadequate response to, or who are intolerant of, conventional therapy. |
| onasemnogene abeparvovec | onasemnogene abeparvovec | Zolgensma | Novartis Europharm Limited | Authorised | 2020-05-18 | 2026-08-21 | EMEA/H/C/004750 | Muscular Atrophy, Spinal | Zolgensma is indicated for the treatment of:patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, orpatients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. |
| avacopan | Avacopan | Tavneos | Vifor Fresenius Medical Care Renal Pharma France | Authorised | 2022-01-11 | 2026-08-21 | EMEA/H/C/005523 | Microscopic Polyangiitis、Wegener Granulomatosis | Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). |
| adagrasib | Adagrasib | Krazati | Bristol-Myers Squibb Pharma EEIG | Authorised | 2024-01-05 | 2026-08-21 | EMEA/H/C/006013 | Carcinoma, Non-Small-Cell Lung | Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy. |
| Rozanolixizumab | Rozanolixizumab | Rystiggo | UCB Pharma | Authorised | 2024-01-05 | 2026-08-21 | EMEA/H/C/005824 | Myasthenia Gravis | Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |
| ranibizumab | ranibizumab | Rimmyrah | Qilu Pharma Spain S.L. | Authorised | 2024-01-05 | 2026-08-21 | EMEA/H/C/006055 | Wet Macular Degeneration、Macular Edema、Diabetes Complications、Myopia, Degenerative、Choroidal Neovascularization | Rimmyrah is indicated in adults for:The treatment of neovascular (wet) age-related macular degeneration (AMD)The treatment of visual impairment due to diabetic macular oedema (DME)The treatment of proliferative diabetic retinopathy (PDR)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)The treatment of visual impairment due to choroidal neovascularisation (CNV) |
| somatrogon | somatrogon | Ngenla | Pfizer Europe MA EEIG | Authorised | 2022-02-14 | 2026-08-21 | EMEA/H/C/005633 | Growth and Development | Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone |
上一页 第 3 / 3 页 下一页